2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate (Atiprimod) induced apoptosis in multiple myeloma (MM) cells

06-21-2006

According to a study from the United States, "MM accounts for 1% of all cancer deaths. Although treated aggressively, almost all myelomas eventually recur and become resistant to treatment."

"Atiprimod has exerted anti-inflammatory activities and inhibited osteoclast-induced bone resorption in animal models and been well tolerated in patients with rheumatoid arthritis in phase I clinical trials. Therefore, we investigated its activity in MM cells and its mechanism of action," explained M. Amitvazina and colleagues, M.D. Anderson Cancer Center.

"We found that Atiprimod inhibited proliferation of the myeloma cell lines U266-B1, OCI-MY5, MM-1, and MM-1R in a time- and dose-dependent manner. Atiprimod blocked U266-B1 myeloma cells in the G0 /G1 phase, preventing cell cycle progression. Furthermore, Atiprimod inhibited signal transducer and activator of transcription (STAT) 3 activation, blocking the signaling pathway of interleukin-6, which contributes to myeloma cell proliferation and survival, and downregulated the antiapoptotic proteins Bcl-2, Bcl-X-L, and Mcl-1," stated the investigators.

"Incubation of U266-B1 myeloma cells with Atiprimod induced apoptosis through the activation of caspase 3 and subsequent cleavage of the DNA repair enzyme poly(adenosine diphosphate-ribose) polymerase. Finally, Atiprimod suppressed myeloma colony-forming cell proliferation in fresh marrow cells from five patients with newly diagnosed MM in a dose-dependent fashion."

The researchers concluded, "These data suggest that Atiprimod has a role in future therapies for MM."

Amitvazina and colleagues published the results of their research in British Journal of Cancer (Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer, 2005;93(1):70-80).

For additional information, contact Z. Estrov, University of Texas, MD Anderson Cancer Center, Dept. Leukemia, Unit 428, 1515 Holcombe Blvd., Houston, TX 77030, USA.

Keywords: Houston, Texas, United States, Animal Models, Antiinflammatory, Apoptosis, Arthritis, Clonogenic Assay, DNA Repair, DNA Research, Deoxyribonucleic Acid, Multiple Myeloma, Nuclear Factor Kappa B, Oncology, Proteomics, Rheumatoid Arthritis, Signal Transduction.

This article was prepared by Cancer Weekly editors from staff and other reports. Copyright 2006, Cancer Weekly via NewsRx.com.



Related Diseases: Multiple Myeloma
Related Keywords: Apoptosis, Atiprimod
Related Glossary Terms: MM
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
New drug combination brings 1-2 punch against acute leukemia
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
St. Jude discovery offers new avenues to understanding an aggressive form of leukemia
Molecular science could further improve leukemia survival say St Jude researchers
Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data
Acute Myeloid Leukemia (AML)
Mile High Amazing Race Downtown Denver 5/17
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine
Molecular change may reveal risk of leukemia relapse
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Function of molecular switch pinpointed in severe congenital neutropenia
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
STEM CELL PROCEDURE SUCCESSFULLY TREATS AMYLOIDOSIS PATIENTS
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
New lymphoma therapies targets diverse and difficult cancer
Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
Easier to predict the future for leukemia patients
Chronic Myeloid Leukemia (CML)
Arsenic-based therapy shown to help eradicate leukemia-initiating cells
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
St. Jude discovery offers new avenues to understanding an aggressive form of leukemia
OHSU Cancer Institute researchers identify new approach to help control drug resistance in leukemia
Nilotinib a Second-Line Treatment for Chronic Myelogenous Leukaemia: Presented at NCCN
Hodgkin Lymphoma
Mile High Amazing Race Downtown Denver 5/17
Stem Cell Transplant Procedures Vary Throughout the World
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Experimental Drug Shows Promise in Treating One Class of Lymphoma
Med BioGene Confirms High Accuracy Rate for LymphExpress Dx
Multiple Myeloma
Lenalidomide raises clot risk in multiple myeloma patients
Immunomedics, Inc. (IMMU)'s Milatuzumab receives FDA orphan drug designation
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
Combination Therapy Effective Against Multiple Myeloma
The Myeloma Landscape in 2008
Myelodysplastic Syndrome (MDS)
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Scoring system identifies MDS patients who have low-risk disease but a poor prognosis
Seattle Genetics Initiates Phase IIb Clinical Trial of SGN-33 in Combination with Chemotherapy for Acute Myeloid Leukemia
Data From Ongoing Hematological Trials With Darinaparsin Presented at European College of Clinical Oncology Annual Meeting
Non-Hodgkin Lymphoma (NHL)
Stem Cell Transplant Procedures Vary Throughout the World
Risk Of Second Cancers Greatest In Younger Patients Treated For Non-Hodgkins Lymphoma
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Experimental Drug Shows Promise in Treating One Class of Lymphoma
Immunomedics Reports Veltuzumab Enhances Radioimmunotherapy With Epratuzumab in Lymphoma Model
Testicular Cancer
Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer
Testicular cancer gauge often not used
Testicular Chromosome Structure and Gene Expression Will Provide an Opportunity to Analyze Male Reproductive Biology and the Processes by Which Sperm Are Formed
Testicular Cancer Therapy Affects Risk of Second Malignancies and CVD
Testicular Cancer Therapy Affects Risk of Second Malignancies and CVD